Literature DB >> 18338266

The effects of hyperprolactinemia on bone and fat.

Amal Shibli-Rahhal1, Janet Schlechte.   

Abstract

Many patients with prolactin secreting pituitary tumors have decreased bone mineral. The bone loss is associated with an increase in bone resorption and is secondary to prolactin-induced hypogonadism. In both sexes trabecular bone in the spine and hip is more affected than cortical bone in the distal radius. Normalization of prolactin and restoration of gonadal function increases bone density but is not associated with normalization of bone mass. It is not known whether the bone loss in hyperprolactinemic subjects represents a failure to achieve peak bone mass or is due to accelerated bone loss. Despite low bone density hyperprolactinemic subjects do not demonstrate increased fractures. The association between prolactin, weight gain and obesity suggests that prolactin may also be a modulator of body composition and body weight. It is not known whether hyperprolactinemia associated weight gain is due to stimulation of lipogenesis or due to disruption of central nervous system dopaminergic tone. Hyperprolactinemia is also associated with insulin resistance and endothelial dysfunction which may improve after normalization of prolactin. The clinical significance of these findings and the precise role of prolactin in regulation of weight and metabolism remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18338266     DOI: 10.1007/s11102-008-0097-3

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  91 in total

1.  Hyperprolactinaemia as a reversible cause of weight gain in male patients?

Authors:  E Delgrange; J Donckier; D Maiter
Journal:  Clin Endocrinol (Oxf)       Date:  1999-02       Impact factor: 3.478

2.  Reversible weight gain and prolactin levels--long-term follow-up in childhood.

Authors:  F Galluzzi; R Salti; S Stagi; F La Cauza; F Chiarelli
Journal:  J Pediatr Endocrinol Metab       Date:  2005-09       Impact factor: 1.634

3.  Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.

Authors:  A Colao; C Di Somma; S Loche; A Di Sarno; M Klain; R Pivonello; M Pietrosante; M Salvatore; G Lombardi
Journal:  Clin Endocrinol (Oxf)       Date:  2000-03       Impact factor: 3.478

Review 4.  Prolactin is an important regulator of intestinal calcium transport.

Authors:  Narattaphol Charoenphandhu; Nateetip Krishnamra
Journal:  Can J Physiol Pharmacol       Date:  2007-06       Impact factor: 2.273

5.  Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism.

Authors:  S L Greenspan; D S Oppenheim; A Klibanski
Journal:  Ann Intern Med       Date:  1989-04-01       Impact factor: 25.391

6.  Osteopenia in women with hypothalamic amenorrhea: a prospective study.

Authors:  B M Biller; J F Coughlin; V Saxe; D Schoenfeld; D I Spratt; A Klibanski
Journal:  Obstet Gynecol       Date:  1991-12       Impact factor: 7.661

7.  Decreased dopaminergic control of prolactin secretion in male obesity: normalization by fasting.

Authors:  S Röjdmark; S Rössner
Journal:  Metabolism       Date:  1991-02       Impact factor: 8.694

8.  Hyperprolactinemia stimulates food intake in the female rat.

Authors:  B J Moore; T Gerardo-Gettens; B A Horwitz; J S Stern
Journal:  Brain Res Bull       Date:  1986-10       Impact factor: 4.077

9.  Bone density in amenorrheic women with and without hyperprolactinemia.

Authors:  J A Schlechte; B Sherman; R Martin
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

10.  Prolactin: a diabetogenic hormone.

Authors:  R Landgraf; M M Landraf-Leurs; A Weissmann; R Hörl; K von Werder; P C Scriba
Journal:  Diabetologia       Date:  1977-04       Impact factor: 10.122

View more
  29 in total

1.  Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.

Authors:  C D Gibson; W Karmally; D J McMahon; S L Wardlaw; J Korner
Journal:  Diabetes Obes Metab       Date:  2011-12-27       Impact factor: 6.577

2.  Mammary gland serotonin regulates parathyroid hormone-related protein and other bone-related signals.

Authors:  Laura L Hernandez; Karen A Gregerson; Nelson D Horseman
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-07       Impact factor: 4.310

3.  Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents.

Authors:  Chadi A Calarge; Stephanie D Ivins; Katherine J Motyl; Amal A Shibli-Rahhal; Michael M Bliziotes; Janet A Schlechte
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

4.  Prolactin activation of the long form of its cognate receptor causes increased visceral fat and obesity in males as shown in transgenic mice expressing only this receptor subtype.

Authors:  J A Le; H M Wilson; A Shehu; Y S Devi; T Aguilar; G Gibori
Journal:  Horm Metab Res       Date:  2011-10-11       Impact factor: 2.936

Review 5.  Treatment of hyperprolactinemia in post-menopausal women: pros.

Authors:  D Iacovazzo; L De Marinis
Journal:  Endocrine       Date:  2014-08-12       Impact factor: 3.633

Review 6.  Concomitant myasthenia gravis and macroprolactinoma: the immunomodulatory role of prolactin and its potential therapeutic use.

Authors:  S M Harris; H M C Leong; R Chowdhury; C Ellis; John Brennan; I N Scobie
Journal:  Endocrine       Date:  2013-06-08       Impact factor: 3.633

7.  Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia.

Authors:  Aysegul Atmaca; Birsen Bilgici; Gulcin Cengiz Ecemis; Ozgur Korhan Tuncel
Journal:  Endocrine       Date:  2013-03-26       Impact factor: 3.633

8.  Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study.

Authors:  Chadi A Calarge; James A Mills; Ekhard E Ziegler; Janet A Schlechte
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-11-07       Impact factor: 2.576

9.  Secondhand tobacco smoke exposure is associated with prolactin but not thyroid stimulating hormone among nonsmoking women seeking in vitro fertilization.

Authors:  Merle D Benedict; Stacey A Missmer; Kelly K Ferguson; Allison F Vitonis; Daniel W Cramer; John D Meeker
Journal:  Environ Toxicol Pharmacol       Date:  2012-09-23       Impact factor: 4.860

10.  Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment.

Authors:  Jeffrey R Bishop; Leah H Rubin; James L Reilly; Mani N Pavuluri; John A Sweeney
Journal:  Ther Adv Psychopharmacol       Date:  2012-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.